DOP64 Steroid-sparing effect of risankizumab vs ustekinumab in patients with moderately to severely active Crohn’s Disease: Post hoc results from the phase 3b SEQUENCE trial

T Raine,S Danese,S Schreiber,X Gao,S Hanauer,J Torres,K Kligys,X Huang,E Neimark,T Anschutz,J Crowley,R K Cross

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0104

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Corticosteroid (CS) dependency and/or resistance occurs in approximately 50% of patients with Crohn’s disease (CD).1 In SEQUENCE, risankizumab (RZB; interleukin [IL]-23 inhibitor) demonstrated superiority over ustekinumab (UST; IL-12/IL-23 inhibitor) for the ranked secondary endpoints of CS-free clinical remission and CS-free endoscopic remission at week 48. In this post hoc analysis, we evaluate the CS-sparing effects of RZB and UST over 48 weeks in patients taking CS at baseline (BL). Methods SEQUENCE (NCT04524611) was an open-label, multicenter, randomised, efficacy assessment-blinded study in adults with moderately to severely active CD who previously failed ≥ 1 anti-tumor necrosis factor (TNF) therapy. Patients in the primary efficacy analysis were randomised 1:1 to receive RZB (intravenous [IV] 600 mg induction dose at weeks 0, 4, and 8, followed by a subcutaneous [SC] 360 mg maintenance dose every 8 weeks starting at week 12) or UST (single weight-based IV induction dose, followed by a SC 90 mg maintenance dose every 8 weeks starting at week 8) up to week 48. A mandatory CS taper started at week 2. CS-free outcomes (clinical remission or endoscopic remission and no CS at the assessed visit) were evaluated among patients taking CS at BL. Nominal P values were reported. Results The primary efficacy analysis included 520 patients (RZB, n = 255; UST, n = 265), and 24.8% (129/520) of patients were taking CS at BL. Demographics and disease characteristics were generally similar between treatment groups and between patients with and without CS use at BL. The mean (SD) daily prednisone-equivalent dose at BL was 21.4 (12.9) mg (RZB) and 19.5 (10.7) mg (UST), respectively. By week 8, more patients treated with RZB vs UST discontinued CS (75.9% vs 59.2%; nominal P < .05). Although a similar proportion of patients in either treatment group discontinued CS at week 24, more patients treated with RZB vs UST discontinued CS at week 48 (86.2% vs 57.7%; nominal P < .001). Of the patients taking CS at BL, RZB vs UST treatment resulted in higher rates of CS-free clinical remission (week 24: RZB, 44.8% vs UST, 33.8%; week 48: RZB, 56.9% vs UST, 31.0%) and CS-free endoscopic remission (week 24: RZB, 34.5% vs UST, 11.3%; week 48: RZB, 32.8% vs UST, 12.7%) (Table 1). Most patients who achieved CS-free outcomes at week 48 were CS-free for 90 days before week 48. Conclusion In patients with CD who previously failed anti-TNF therapy, RZB was more effective than UST for discontinuing CS use and achieving CS-free clinical and endoscopic remission. References: 1. Lichtenstein G., et al. Am J Gastroenterol. 2018;113:481−517

gastroenterology & hepatology